OXB SOLUTIONS
LIVE

Serial Number

97361213

Owner

Oxford BioMedica plc

Attorney

Roberta S. Bren

Filing Date

Apr 13, 2022

Add to watchlist:

No watchlists yet
View on USPTO

OXB SOLUTIONS Trademark

Serial Number: 97361213 • Registration: 7683507

OXB SOLUTIONS is a trademark filed by Oxford BioMedica plc on April 13, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Oxford BioMedica plc (54 trademarks)

Medawar Centre, Robert Robinson Avenue
Oxford, OX4 4GA , GB

Entity Type: 03

Trademark Details

Filing Date

April 13, 2022

Registration Date

February 11, 2025

Published for Opposition

October 31, 2023

Goods & Services

Custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; manufacture of biotechnology products; manufacture of viral and non-viral vectors; manufacture of vaccines

Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases, vaccines; pharmaceutical substances and preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; gene therapy products, namely, nanoparticles, viral vectors, retroviral vectors, lentiviral vectors and non-viral vectors for the delivery of genes to cells, all for medical purposes; vaccine manufacturing preparations; viral vaccines, namely, viral vector, retroviral vector, lentiviral vector and non-viral vector preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; biochemical and chemical products for use in medical science, namely, viral vectors; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes

Preparation and review of reports for regulatory approval of pharmaceuticals and bioceuticals; licensing of intellectual property; regulatory compliance consulting in the field of chemistry manufacturing and controls (CMC) activities

Medical diagnostic testing; information relating to pharmaceuticals, bioceuticals and advanced therapy medicinal products; providing medical information to medical professionals in the form of reports in the field of biotechnology, gene therapy and cell therapy; consultancy, advice and information in the field of clinical trials, healthcare, pharmaceuticals and advanced therapy medicinal products; medical advisory services relating to vaccination regimes; medical advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, and pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animals

Scientific research and development services in the field of biochemistry and genetic engineering; biochemistry engineering; genetic engineering; design of manufacturing facilities; quality control for others; scientific and technological services, namely, testing and validation services in the fields of gene and cell therapy and biotechnology; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; medical and scientific laboratory services; scientific and technological services, namely, scientific research, development and analysis in the fields of gene and cell therapy and biotechnology; industrial analysis services, namely, analysis of viral vectors and gene therapy products to assure compliance with medical and pharmaceutical industry standards; provision of scientific information in the field of biotechnology, gene therapy and cell therapy; research and scientific analysis relating to drug discovery and development for others; scientific research in the nature of conducting clinical trials for others; manufacture of viral vectors, gene therapy and cell therapy products; product and manufacturing process development in the fields of biotechnology, gene therapy and cell therapy

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 11, 2025 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jan 17, 2025 DP1B
NOTICE OF ALLOWANCE CANCELLED
Jun 24, 2024 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Jun 24, 2024 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 26, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 31, 2023 NPUB
PUBLISHED FOR OPPOSITION
Oct 31, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 11, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 20, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 14, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 14, 2023 CRFA
ASSIGNED TO LIE
Sep 14, 2023 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 28, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 3, 2023 GNRN
NON-FINAL ACTION E-MAILED
Feb 3, 2023 GNRT
NON-FINAL ACTION WRITTEN
Feb 3, 2023 CNRT
ASSIGNED TO EXAMINER
Jan 31, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 19, 2022 NWOS
NEW APPLICATION ENTERED
Apr 16, 2022 NWAP